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Abstract  
Autoimmune neurological syndromes (ANS) can be paraneoplastic or non-paraneoplastic. Their 
clinical presentation is often similar. Better biomarkers are needed to rapidly identify patients with 
tumors. We investigated cerebrospinal fluid (CSF) levels of commercially available markers of 
neuronal (neurofilament light chain = NFL, total tau protein = T-tau) and glial (glial fibrillary acidic 
protein) damage in patients with ANS. CSF-NFL and T-tau were increased in both paraneoplastic and 
non-paraneoplastic cases. Patients with malignancies had increased CSF-NFL, CSF-blood albumin 
ratio, and worse long-term outcome, compared with those without. CSF-NFL levels predicted long-
term outcome but were not diagnostic for malignancy after age adjustment. 
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Introduction 
Autoimmune neurological syndromes (ANS) may manifest with peripheral, as well as central nervous 
system dysfunction. ANS may be associated with peripheral tumors (i.e. be paraneoplastic – PaNS) or 
not (i.e. be non-paraneoplastic – non-PaNS).  
Clinical presentation of ANS is variable and often does not allow direct identification of patients with 
malignancies. Detection of peripheral tumors can be difficult and involve many investigations that 
often need to be repeated. Identification and treatment of tumors is nonetheless imperative for 
improving long-term prognosis (Darnell and Posner, 2003, Graus and Dalmau, 2007, Gromadzka et 
al., 2013, Titulaer et al., 2011). Cerebrospinal fluid (CSF) analysis, brain magnetic resonance imaging 
(MRI) and antibody testing often cannot help in differentiating between patients with malignancies 
and those without (Psimaras et al., 2010, Graus et al., 2016, Dalmau et al., 2011). There is a clear need 
for better and clinically accessible biomarkers to rapidly identify patients with an underlying 
malignancy.  
 
In patients with autoimmune encephalitis, increased CSF levels of neurofilament light chain (NFL) 
and total tau protein (T-tau) (neuronal damage markers), but not of glial fibrillary acidic protein 
(GFAP) (marker of glial damage) were recently found (Constantinescu et al., 2016). These markers 
were not yet studied separately in patients with underlying malignancies and those without. The aim of 
this study is to investigate patients with paraneoplastic and non-paraneoplastic ANS and compare 
those with malignancies with those without, in an attempt to identify characteristic clinical and 
laboratory patterns. 
 
 
Patients and methods 
Ethics 
The retrospective design of this study was approved by the Regional Ethical Board at the University of 
Gothenburg. All medical procedures were performed only for clinical reasons. 
Patients 
Patients with autoimmune neurological syndromes were identified by searching patient files using 
combinations of two search terms: (1) “autoimmune, limbic, paramalignant, malignant or 
paraneoplastic” AND (2) “encephalitis, syndrome, phenomenon”. Data of identified patients were then 
extracted and verified manually. 
For study inclusion, following criteria were needed: (I) Definite or possible PaNS according to Graus 
et al., 2004 (Graus et al., 2004) OR possible autoimmune encephalitis according to Graus et al., 2016 
(Graus et al., 2016); AND (II) Results from at least one CSF analysis; AND (3) Exclusion of other 
diagnoses with a similar clinical presentation (Asztely and Kumlien, 2012, Zuliani et al., 2012, Graus 
et al., 2008). 
Diagnostic workup 
Investigations included brain MRI, EEG, CSF and blood analyses. Oncoscreening included computer 
tomography (CT) of abdomen and chest, ultrasound of testes, gynecological evaluation and 
mammography in women. When no malignancy was found, a whole body positron emission 
tomography with whole-body CT (18FDG-PET/CT) was performed. Oncoscreening was repeated at 
regular intervals, as recommended (Titulaer et al., 2011). 
Cerebrospinal fluid analysis 
Routine CSF investigation included: cell count, cytology, CSF levels of albumin, IgG and IgM with 
calculation of the CSF/serum albumin ratio, IgG index and IgM index, isoelectric focusing of paired 
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CSF and serum samples to identify CSF-specific oligoclonal IgG bands, and in cases with high IgM 
index agarose electrophoresis and western blotting to identify CSF specific oligoclonal IgM bands.  
CSF immunopathy was defined as the presence of at least one of the following: (a) pleocytosis (>3x106 
cells/L), (b) CSF-specific oligoclonal immunoglobulin G (IgG) bands (>1 CSF-selective band), (c) 
increased albumin ratio (>6.2), (d) increased IgG index (>0.63), or increased IgM index (>0,060). 
Increased CSF-albumin (>320 mg/L) and/or increased CSF to serum albumin ratio (>6.8) were 
considered as a sign of blood-brain barrier damage. 
CSF-NFL, T-tau and GFAP were measured as previously reported (Constantinescu et al., 2016) – see 
also Supplementary section. 
Neuronal surface antibodies and antibodies against intracellular antigens 
Antibodies were measured in both serum and CSF. The following antibodies were examined: (1) 
Well-characterized onconeural antibodies against antigens -Hu, -Yo, -Ri, -Ma2/Ta,-CV2/CRMP5 and 
-amphiphysin; (2) Neuronal surface antibodies: antibody against N-methyl-D-aspartate receptor 
(NMDAR); γ-aminobutyric acid receptor B (GABABR); α-amino-3-hydroxy-5-methyl-4- 
isoxazolepropionic acid receptors 1 and 2 (AMPA1,2); leucine-rich glioma inactivated protein 1 
(LGI1); contactin-associated protein 2 (CASPR2); (3) Other: anti-GAD and antimicrosomal antibodies 
(anti-TPO). Commercial kits (Euroimmun AG) were used for antibody measurement, as described in 
our previous study (Constantinescu et al., 2016). See also the Supplementary section. 
Outcome 
Outcome was assessed retrospectively from patient files, as the level of disability at the last 
documented follow-up, using the modified Rankin Scale (mRS) (Rankin, 1957, Farrell et al., 1991) 
and the Karnofsky Performance Status scale (Crooks et al., 1991).  
Statistical analysis 
SPSS statistics package was used for analysis. The Independent-Samples Mann-Whitney U-test, 
Kruskal-Wallis test, and cross-tabulation were used as appropriate.  Associations were calculated with 
Fisher’s exact test, Pearson Chi-Square test, partial correlations with age adjustment, and with logistic 
regression as appropriate. All tests were two tailed with p ≤ 0.05 as the level of significance.  
Results: 
Demographics (Table 1) 
Thirty-seven patients (14 males/ 23 females) fulfilled the inclusion criteria. Twelve had a peripheral 
malignancy and 25 did not. No gender differences were found, but patients with tumors were 
significantly older (median 72 vs. 42 years, p<0.001).  
Clinical presentation 
The following diagnoses were recorded: (1) Definite PaNS, N=14; (2) Possible PaNS, N=2; (3) 
Possible autoimmune encephalitis, N= 21. Patients with tumors were more likely to seek medical 
attention later, and to have more focal, specific, central and peripheral neurological signs and 
symptoms. Cognitive and psychiatric disturbances were equally common, but epilepsy and status 
epilepticus were more prevalent in patients without malignancies.  
Malignancies 
Twelve patients had malignancies. It could take several months until malignancy findings were 
positive and in one case malignancy was only found post mortem, 15 months after the onset of 
neurological symptoms.  
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Antibodies (Supplementary Table 2) 
Single or multiple antibodies were found in serum or CSF in 7/12 (58 %) patients with malignancies 
and in 13/25 (52 %) patients without.  
CSF immunopathy markers (Supplementary Table 3) 
CSF-serum albumin ratio was significantly higher in patients with malignancies compared with 
patients without (p=0.035), as a sign of blood-brain barrier damage.  
Brain imaging 
There were no significant differences among patients with and without malignancies in respect to MRI 
findings (normal or pathological). 
Brain damage markers (Table 2 and Figure 1 (a,b, c)) 
CSF-NFL and CSF-T-tau levels were high in both PaNS and non-PaNS patients, compared with 
reference values. CSF-GFAP was not significantly increased. CSF-NFL levels were significantly 
higher in patients with malignancies compared with those without (p=0,004). In the logistical 
regression model with age as a covariate, malignancies were not significantly correlated with any brain 
damage marker. 
Outcome (Supplementary Table 1) 
Level of disability at the last follow up (measured by Karnofsky Performance State scale and mRS) 
was significantly higher in patients with malignancies (p=0.003 and 0.002).  In the group as a whole, 
disability was correlated with CSF-NFL (after age adjustment) (p=0.001), but not with CSF-T-tau or 
CSF-GFAP. Malignancies were associated with higher mortality (p=?). 
Discussion 
We found that levels of CSF-NFL and CSF-T-tau (neuronal damage markers) but not of CSF-GFAP 
(glial damage marker) were increased in both paraneoplastic and non-paraneoplastic ANS. Patients 
with underlying malignancies had significantly higher CSF-NFL levels, higher CSF-blood albumin 
ratios, more often focal neurological signs and symptoms, less often seizures and status epilepticus, 
worse long-term outcome, and were older compared with patients without detectable malignancies. 
After correcting for age, CSF-NFL was not significantly associated with malignancy, but it was related 
to the long-term outcome.  
High levels of CSF-NFL and T-tau in ANS was an expected finding, because CSF-NFL and T-tau are 
increased non-specifically in patients with various brain disorders and indicate axonal and neuronal 
injury (Norgren et al., 2003, Blennow et al., 2010). Neuronal death due to inflammatory processes in 
ANS has already been demonstrated (Psimaras et al., 2010, Giometto et al., 1997). The novelty of our 
study is 1) to show for the first time the trend for increased neuronal injury (reflected in CSF-NFL 
levels) in PaNS, and 2) to suggest that long-term outcome in ANS appears to be correlated with CSF-
NFL levels measured in proximity to disease onset. This expands our previous observations in 
autoimmune encephalitis (Constantinescu et al., 2016) and warrants the evaluation of prognostic 
significance of CSF-NFL in these disorders. Our findings indicate that severely elevated CSF-NFL, 
especially in older patients with ANS without status epilepticus could suggest the presence of an 
underlying malignancy. However, this finding needs to be confirmed in larger, prospective studies. 
The absence of significant differences in regards to MRI findings, autoantibodies and markers of 
immunopathy between patients with malignancies and those without and the long delay to a 
malignancy diagnosis observed in one case illustrate again the need for better diagnostic biomarkers in 
this context, and reinforces further study of CSF-NFL’s potential in this respect.  
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Major limitations of this study are the retrospective design and relatively low number of patients 
included. The choice of search terms may have focused too narrowly on autoimmune encephalitis and 
PaNS while omitting other types of autoimmune neurological syndromes. Due to these limitations, the 
study needs to be replicated prospectively on a larger patient cohort.  
 
Tables 
Table 1. Demographics. Numbers represent median (range). Groups were compared using the Fisher’s 
exact test and Independent samples Mann-Whitney U-test. 
 N (males/ 
females) 
Age at LP 
(years) 
Symptom duration at 
LP (months) 
Follow-up time 
(years) 
Malignancy 12 (5/7) 72  
(53-81) 
2.1  
(0.2-27.6) 
1.6  
(0.3-8.8) 
No 
malignancy 
25 (9/16) 42  
(17-75) 
0,7  
(0.0-24.4) 
4.2  
(0.6-10-3) 
p 0.507 <0.001 0.21 0.008 
Abbreviations (in alphabetical order): LP=lumbar puncture 
 
Table 2. CSF-levels of brain damage markers in patients with paraneoplastic neurological syndromes, 
non-paraneoplastic neurological syndromes, in patients with malignancies, and in patients without 
malignances. Values are expressed in ng/L. The reference values are given for orientation and 
represent the upper limits of the reference range for the highest age groups (> 70 years for NFL, and > 
60 years for GFAP and T-tau). These limits are lower for younger age groups. For details see 
Supplementary Table 4. Groups were compared using the Independent samples Mann-Whitney U-test. 
Abbreviations (in alphabetical order): CSF = cerebrospinal fluid; GFAP = glial fibrillary acidic 
protein; NFL = neurofilament light chain protein; Non-PaNS = non-paraneoplastic neurological 
syndrome; PaNS = paraneoplastic neurological syndrome (including definite and possible (Graus et 
al., 2004); T-tau = total tau protein. 
NFL  GFAP T-tau  
Mean Median Range Mean Median Range Mean Median Range 
PaNS 29007 9277 781-
127478 
750 605 120-
1650 
1317 635 130-
6910 
Non-PaNS 6172 1440 180-
54063 
646 320 50-
2450 
1224 541 100-
5690 
p <0.001 0.096 0.907 
Malignancy 33491 13297 2820-
127478 
878 700 120-
1650 
894 570 130-
2520 
No 
malignancy 
7440 1800 180-
54063 
624 380 50-
2450 
1407 560 100-
6910 
p 0.001 0.630 0.733 
Reference 
values 
<1850 <1250 <400 
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Figure 1 (a,b,c): Levels of brain damage markers in the cerebrospinal fluid (CSF) from patients with 
different types of autoimmune neurological syndromes, with and without peripheral malignancies. 
Dashed line represents the highest upper limits of the reference range. (a) Levels of neurofilament 
light chain (NFL) were significantly increased in patients with malignancies compared with those 
without. However, in a logistical regression model including age as a covariate, none of the brain 
damage markers (including CSF-NFL) were associated with malignancy; (b) Glial fibrillary acidic 
protein (GFAP) protein; and (c) total tau (T-tau) protein. Abbreviations (in alphabetical order): CSF 
= cerebrospinal fluid; GFAP = glial fibrillary acidic protein; NFL = neurofilament light chain protein; 
T-tau = total tau protein. 
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